BPTS:NSD-Biophytis SA (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.35

Change

-0.23 (-4.18)%

Market Cap

USD 0.08B

Volume

1.05K

Avg Analyst Target

USD 15.00 (+180.53%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Biophytis SA (BPTS) Stock Analysis:
Based on the Biophytis SA stock forecasts from 1 analysts, the average analyst target price for Biophytis SA is USD 15.00 over the next 12 months. Biophytis SA’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biophytis SA is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Biophytis SA’s stock price was USD 5.35. Biophytis SA’s stock price has changed by -0.41 % over the past week, -0.99 % over the past month and +0.00 % over the last year.

About

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffe ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+5.23 (+1.73%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

+10.57 (+3.17%)

USD87.92B 10.55 8.07
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.18%)

USD67.82B 10.14 7.73
VRTX Vertex Pharmaceuticals Incorpo..

-0.64 (-0.31%)

USD48.34B 24.52 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-31.73 (-9.17%)

USD33.38B N/A N/A
SGEN Seagen Inc

-7.93 (-5.00%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.30 (-0.80%)

USD25.21B 56.53 6.26
ALNY Alnylam Pharmaceuticals Inc

-11.49 (-6.28%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BPTS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.08B 19% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.62 10% F 10% F
Price / Cash Flow Ratio -7.80 55% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -3,271.93% 2% F 9% F
Return on Invested Capital -117.61% 14% F 6% F
Return on Assets -39.53% 21% F 7% F
Debt to Equity Ratio 26.71% 35% F 53% F
Technical Ratios  
Short Ratio 2.07 70% C- 59% F
Short Percent 0.02% 100% A+ 98% A+
Beta 1.06 60% D- 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector